Prostate Cancer and Prostatic Diseases最新文献

筛选
英文 中文
Single-port transvesical simple prostatectomy for the surgical treatment of benign prostatic hyperplasia: functional and continence outcomes. 用于良性前列腺增生手术治疗的单孔经膀胱单纯前列腺切除术:功能和尿失禁疗效。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-19 DOI: 10.1038/s41391-024-00923-y
Matteo Pacini, Luca Lambertini, Giulio Avesani, Juan R Torres Anguiano, Luca Morgantini, Alec Martin, Ruben Sauer Calvo, Hakan B Haberal, Gabriele Bignante, Andrea Minervini, Alessandro Zucchi, Riccardo Bartoletti, Simone Crivellaro
{"title":"Single-port transvesical simple prostatectomy for the surgical treatment of benign prostatic hyperplasia: functional and continence outcomes.","authors":"Matteo Pacini, Luca Lambertini, Giulio Avesani, Juan R Torres Anguiano, Luca Morgantini, Alec Martin, Ruben Sauer Calvo, Hakan B Haberal, Gabriele Bignante, Andrea Minervini, Alessandro Zucchi, Riccardo Bartoletti, Simone Crivellaro","doi":"10.1038/s41391-024-00923-y","DOIUrl":"https://doi.org/10.1038/s41391-024-00923-y","url":null,"abstract":"<p><strong>Background: </strong>Robot-Assisted Simple Prostatectomy (RASP) is recommended for the treatment of large prostate glands. The introduction of the Single-Port (SP) platform in 2018 has enabled transvesical approach to SP-RASP with promising outcomes. Our aim was to describe the functional and urinary continence outcomes of SP-RASP.</p><p><strong>Methods: </strong>Clinical and surgical data from all consecutive patients who underwent transvesical SP-RASP between February 2020 and March 2024 were collected in a prospectively maintained institutional dataset and retrospectively analyzed. All procedures were performed using the da Vinci SP platform without any conversions to open surgery. Postoperative outcomes were gathered and analyzed, with a particular focus on the incidence of urinary incontinence (UI) and the time to continence recovery.</p><p><strong>Results: </strong>Overall, 89 patients underwent SP-RASP, with a median prostate size of 110 grams (90-171.5) and a median PSA level of 5.5 mg/dl (2.77-10.93). All patients were on at least one prostate medication prior to surgery. Preoperative evaluations showed a median International Prostate Symptoms Score (IPSS) of 23 (20-27), Quality of Life (QoL) of 4 (3-5), and Post-voiding Residual (PVR) of 153 ml (60-400). The median operative time was 180 min (164-200), with a median estimated blood loss of 100 ml (30-180). Postoperatively, no patients required continuous bladder irrigation. The median postoperative opioid intake was 6.5 morphine equivalents (0-10), with over 78% not requiring narcotics after discharge. Overall, 77.5% were same day discharged. No Clavien-Dindo > 2 complications were recorded. The median follow-up time was 18 (7-35) months. At the last postoperative urological evaluation, the median IPSS was 5 (3-7), QoL was 1 (0-2), and PVR was 10 ml (0-25). Only 4 patients (4.5%) experienced UI postoperatively, and all were continent within 3 months.</p><p><strong>Conclusions: </strong>The UI incidence rate and functional outcomes of SP-RASP are very encouraging, likely due to precise adenoma and urethra dissection and bladder neck reconstruction. This approach also allows for same-day discharge.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer. MDT视角:立体定向体放射治疗在转移性阉割耐药前列腺癌中的创新应用。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-18 DOI: 10.1038/s41391-024-00922-z
Andrew W Hahn, Ana Aparicio, Hossein Jadvar, Darren M C Poon
{"title":"MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.","authors":"Andrew W Hahn, Ana Aparicio, Hossein Jadvar, Darren M C Poon","doi":"10.1038/s41391-024-00922-z","DOIUrl":"10.1038/s41391-024-00922-z","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers. 通过新型有效组织生物标记物加强局部前列腺癌的风险分层模型。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-14 DOI: 10.1038/s41391-024-00918-9
Csilla Olah, Fabian Mairinger, Michael Wessolly, Steven Joniau, Martin Spahn, Marianna Kruithof-de Julio, Boris Hadaschik, Aron Soós, Péter Nyirády, Balázs Győrffy, Henning Reis, Tibor Szarvas
{"title":"Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.","authors":"Csilla Olah, Fabian Mairinger, Michael Wessolly, Steven Joniau, Martin Spahn, Marianna Kruithof-de Julio, Boris Hadaschik, Aron Soós, Péter Nyirády, Balázs Győrffy, Henning Reis, Tibor Szarvas","doi":"10.1038/s41391-024-00918-9","DOIUrl":"https://doi.org/10.1038/s41391-024-00918-9","url":null,"abstract":"<p><strong>Background: </strong>Localized prostate cancer (PCa) is a largely heterogeneous disease regarding its clinical behavior. Current risk stratification relies on clinicopathological parameters and distinguishing between indolent and aggressive cases remains challenging. To improve risk stratification, we aimed to identify new prognostic markers for PCa.</p><p><strong>Methods: </strong>We performed an in silico analysis on publicly available PCa transcriptome datasets. The top 20 prognostic genes were assessed in PCa tissue samples of our institutional cohort (n = 92) using the NanoString nCounter technology. The three most promising candidates were further assessed by immunohistochemistry (IHC) in an institutional (n = 121) and an independent validation cohort from the EMPACT consortium (n = 199). Cancer-specific survival (CSS) and progression-free survival (PFS) were used as endpoints.</p><p><strong>Results: </strong>Our in silico analysis identified 113 prognostic genes. The prognostic values of seven of the top 20 genes were confirmed in our institutional radical prostatectomy (RPE) cohort. Low CENPO, P2RX5, ABCC5 as well as high ASF1B, NCAPH, UBE2C, and ZWINT gene expressions were associated with shorter CSS. IHC analysis confirmed the significant associations between NCAPH and UBE2C staining and worse CSS. In the external validation cohort, higher NCAPH and ZWINT protein expressions were associated with shorter PFS. The combination of the newly identified tissue protein markers improved standard risk stratification models, such as D'Amico, CAPRA, and Cambridge prognostic groups.</p><p><strong>Conclusions: </strong>We identified and validated high tissue levels of NCAPH, UBE2C, and ZWINT as novel prognostic risk factors in clinically localized PCa patients. The use of these markers can improve routinely used risk estimation models.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostatic stents: a systematic review and analysis of functional outcomes and complication rate. 前列腺支架:功能性结果和并发症发生率的系统回顾与分析。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-08 DOI: 10.1038/s41391-024-00915-y
Clara Cerrato, Vaki Antoniou, Bhaskar Kumar Somani
{"title":"Prostatic stents: a systematic review and analysis of functional outcomes and complication rate.","authors":"Clara Cerrato, Vaki Antoniou, Bhaskar Kumar Somani","doi":"10.1038/s41391-024-00915-y","DOIUrl":"https://doi.org/10.1038/s41391-024-00915-y","url":null,"abstract":"<p><strong>Background: </strong>This review aims to identify and summarize the current literature on the use of prostatic stents or nitinol devices as minimally invasive techniques for the management of lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH).</p><p><strong>Methods: </strong>A comprehensive search of the literature was conducted until October 2023. Only original articles written in English were considered for inclusion. This review has been registered in PROSPERO (registration number CRD42023474884).</p><p><strong>Results: </strong>Thirty-eight articles were included (2618 patients). Generally, the risk of bias was deemed as high or very high. The most frequently investigated stents were the UroLume, followed by the Memokath/Memotherm. The mean age was 72.01 ± 5.6 years, with a mean prostate volume of 48.27 ± 12.8 cc and a mean urethral length of 40.53 ± 9.16 mm. Surgeries were usually performed under local anesthesia. The rates of catheter-free status and complications were 85.2% and 30.83%, respectively. The primary complications included urinary tract infections (17.2%), followed by calcifications (12.6%), irritative symptoms (12.2%), and acute urinary retention (10.4%). During a follow-up period of 12 months, the failure rate intended as stent removal or repositioning was 14.8%. The International Prostate Symptom Score (IPSS) showed an overall improvement of 9.85 points. The mean improvement in maximum flow rate and post-void residual volume were 6.62 ml/sec and 147 ml, respectively.</p><p><strong>Conclusions: </strong>Prostatic stents remain an efficient choice for addressing obstructive symptoms from BPH, offering the advantage of being performed under local anaesthesia, relieving symptoms with good functional outcomes and a low incidence of major complications. Prospective studies are needed to corroborate these results.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. 全面回顾前列腺癌心血管疾病:流行病学、风险因素、治疗和预防策略。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-06 DOI: 10.1038/s41391-024-00897-x
Joseph Moryousef, Wilhelmina Duivenvoorden, Darryl Leong, Jehonathan H Pinthus
{"title":"Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.","authors":"Joseph Moryousef, Wilhelmina Duivenvoorden, Darryl Leong, Jehonathan H Pinthus","doi":"10.1038/s41391-024-00897-x","DOIUrl":"https://doi.org/10.1038/s41391-024-00897-x","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of cardiovascular risk factors and disease is high in patients with newly diagnosed prostate cancer (PC). Survivorship of PC patients is often determined by cardiovascular disease (CVD). Our review synthesizes the most recent literature exploring the dynamics between PC and CVD across the disease trajectory and treatments. We review key ongoing clinical trials in the field and highlight avenues for future study.</p><p><strong>Methods: </strong>We conducted a comprehensive narrative review of the literature using various search strategies in three databases (PubMed, Web of Science, ClinicalTrials.gov), focusing on literature published between 2000 and 2024.</p><p><strong>Results: </strong>We discuss the significance of CVD-related mortality in PC, review the risk factors, and highlight potential mechanisms for accelerated CVD in the androgen-deprivation setting. Furthermore, we summarize key literature of CVD and cardiotoxicity for various therapeutic approaches in PC, including orchiectomy, taxane-based chemotherapy, GnRH-axis targets, and next-generation hormonal agents and PARP inhibitors. Lastly, we discuss prevention strategies and the importance of multi-disciplinary care in this setting.</p><p><strong>Conclusion: </strong>CVD is a major cause of death in men with PC. Various novel therapeutic approaches have been pivotal in improving oncologic outcomes, but emerging data demonstrate a complex interplay between the androgen axis and CVD that is likely affected by modern treatment strategies. Given the prolonged PC survivorship, unraveling non-oncologic related causes of death and investigating prevention strategies are imperative (Fig. 1). Fig. 1 LANDSCAPE OF PROSTATE CANCER.: Spectrum of prostate cancer disease states (red) and interventions (yellow) with the potential role for optimization (green) to improve cardiovascular outcomes in the future (blue).</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming barriers to prostate cancer genetic testing: who, when, and how. 克服前列腺癌基因检测的障碍:谁、何时以及如何检测。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-05 DOI: 10.1038/s41391-024-00916-x
Jun Luo
{"title":"Overcoming barriers to prostate cancer genetic testing: who, when, and how.","authors":"Jun Luo","doi":"10.1038/s41391-024-00916-x","DOIUrl":"https://doi.org/10.1038/s41391-024-00916-x","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection. 对初始 mpMRI 目标阴性和系统活检 PI-RADS ≥ 3 病变的患者进行随访--加强前列腺癌检测的 EAU-YAU 研究。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-05 DOI: 10.1038/s41391-024-00904-1
Fabio Zattoni, Giorgio Gandaglia, Roderick C N van den Bergh, Giancarlo Marra, Massimo Valerio, Alberto Martini, Jonathan Olivier, Ignacio Puche-SanzI, Pawel Rajwa, Martina Maggi, Riccardo Campi, Rossella Nicoletti, Daniele Amparore, Sabrina De Cillis, Junlong Zhuang, Hongqian Guo, Andrea Fuschi, Alessandro Veccia, Francesco Ditonno, Leonor J Paulino Pereira, Alessandro Marquis, Francesco Barletta, Riccardo Leni, Veeru Kasivisvanathan, Alessandro Antonelli, Juan Gomez Rivas, Sebastiaan Remmers, Monique J Roobol, Alberto Briganti, Fabrizio Dal Moro, Giacomo Novara
{"title":"Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection.","authors":"Fabio Zattoni, Giorgio Gandaglia, Roderick C N van den Bergh, Giancarlo Marra, Massimo Valerio, Alberto Martini, Jonathan Olivier, Ignacio Puche-SanzI, Pawel Rajwa, Martina Maggi, Riccardo Campi, Rossella Nicoletti, Daniele Amparore, Sabrina De Cillis, Junlong Zhuang, Hongqian Guo, Andrea Fuschi, Alessandro Veccia, Francesco Ditonno, Leonor J Paulino Pereira, Alessandro Marquis, Francesco Barletta, Riccardo Leni, Veeru Kasivisvanathan, Alessandro Antonelli, Juan Gomez Rivas, Sebastiaan Remmers, Monique J Roobol, Alberto Briganti, Fabrizio Dal Moro, Giacomo Novara","doi":"10.1038/s41391-024-00904-1","DOIUrl":"10.1038/s41391-024-00904-1","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the detection and predictors of prostate cancer (PCA) and clinically significant prostate cancer (csPCA) in patients with positive multiparametric MRI (mpMRI) followed by a negative MRI - guided target biopsy (TB) and systematic biopsy (SB).</p><p><strong>Materials and methods: </strong>This retrospective multicenter study included 694 patients from 10 tertiary referral centers with an initial positive mpMRI (PI-RADS ≥ 3) and negative results on both MRI-TB and SB. Patients were classified into three groups based on follow-up: Group 1 (prostate re-biopsy without new mpMRI), Group 2 (standardized second prostate mpMRI and subsequent re-biopsy), and Group 3 (follow-up with mpMRIs and biopsy based on clinical and radiological triggers). The primary outcomes were the detection of any PCA and csPCA during follow up. Study groups were compared according to their probability of PCA and csPCA assessed with the ERSPC-MRI risk calculator. Statistical analysis included Kaplan - Meier analysis, Cox regression, and multivariable analysis for the detection of (cs)PCa.</p><p><strong>Results: </strong>The overall detection of PCA and csPCA was 26.8% and 19.3%, respectively, with varying rates in different PI-RADS groups. Group 3 had the highest 2-year and 5-year PCA-free survival (94 and 84%) and csPCA - free survival (96 and 86%). Multivariable analysis revealed a significantly higher risk of PCA and csPCA in Group 1 and 2 compared to Group 3 (p < 0.01). Clinical and radiological predictors for PCA and csPCA included higher age, prostate volume, PI-RADS score, the presence of atypical small acinar proliferation (ASAP), and a smaller number of TB and SB performed during the initial biopsy. Study limitations, include the retrospective design and reliance on clinical and radiological triggers for follow-up decisions.</p><p><strong>Conclusions: </strong>Patients with positive mpMRI but negative TB and SB results exhibit varying rates of PCA and csPCA depending on the follow up scheme. Tailored follow-up strategies are essential for optimal management in this clinical scenario.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer detection: achieving an optimal balance. 前列腺癌检测:实现最佳平衡。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-11-04 DOI: 10.1038/s41391-024-00917-w
Jun Luo
{"title":"Prostate cancer detection: achieving an optimal balance.","authors":"Jun Luo","doi":"10.1038/s41391-024-00917-w","DOIUrl":"10.1038/s41391-024-00917-w","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis. 成熟的病灶疗法--HIFU、IRE 或冷冻疗法--我们现在在哪里?
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-10-28 DOI: 10.1038/s41391-024-00911-2
Kae Jack Tay, Khi Yung Fong, Armando Stabile, Jose Luis Dominguez-Escrig, Osamu Ukimura, Lara Rodriguez-Sanchez, Andreas Blana, Ezequiel Becher, M Pilar Laguna
{"title":"Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis.","authors":"Kae Jack Tay, Khi Yung Fong, Armando Stabile, Jose Luis Dominguez-Escrig, Osamu Ukimura, Lara Rodriguez-Sanchez, Andreas Blana, Ezequiel Becher, M Pilar Laguna","doi":"10.1038/s41391-024-00911-2","DOIUrl":"10.1038/s41391-024-00911-2","url":null,"abstract":"<p><strong>Introduction: </strong>Focal Therapy (FT) is a treatment option for the treatment of limited volume clinically significant prostate cancer (csPCa). We aim to systematically review outcomes of established FT modalities to assess the contemporary baseline and identify gaps in evidence that will aid in further trial and study design.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of all primary studies reporting outcomes of FT using cryotherapy, high-intensity focused ultrasound (HIFU), and irreversible electroporation (IRE). We described patient inclusion criteria, selection tools, treatment parameters, and surveillance protocols, and pooled overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), biochemical progression (BP), biopsy, secondary treatment, sexual, and urinary function outcomes. Composite failure was defined as salvage whole gland ablation, radical treatment, hormonal therapy or transition to watchful waiting.</p><p><strong>Synthesis: </strong>We identified 49 unique cohorts of men undergoing FT between 2008 and 2024 (21 cryotherapy, 20 HIFU, and 8 IRE). Median follow-up ranged from 6 to 63 months. Pooled OS was 98.0%, CSS 99.3%, and MFS 98.5%. Pooled BP was 9.4%/year. Biopsy was mandated post-FT within 24 months in 36/49 (73.5%) cohorts, with pooled csPCa (GG ≥ 2) rates of 22.2% overall, 8.9% infield, and 12.3% outfield. The pooled rate of secondary FT was 5.0%, radical treatment 10.5%, and composite failure 14.1%. Of 35 studies reporting sexual function, 45.7% reported a low, 48.6% moderate, and 5.7% severe impact. For 34 cohorts reporting urinary function, 97.1% reported a low impact. No differences were noted between cryotherapy, HIFU, or IRE in any of the outcomes.</p><p><strong>Conclusion: </strong>FT with cryotherapy, HIFU, and IRE is associated with good short-intermediate term oncological and functional outcomes. However, outcome reporting is heterogeneous and often incomplete. Long-term follow-up and standardized reporting are required to better define and report FT outcomes.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study. 健康的社会决定因素与微创前列腺癌根治术的手术效果:一项基于全国人口的研究。
IF 5.1 2区 医学
Prostate Cancer and Prostatic Diseases Pub Date : 2024-10-24 DOI: 10.1038/s41391-024-00913-0
Spencer M Mossack, Antonio Franco, Daniel F Roadman, Morgan R Sturgis, Angelo Orsini, Gabriele Bignante, Francesco Lasorsa, Christopher L Coogan, Edward E Cherullo, Cosimo De Nunzio, Riccardo Autorino
{"title":"Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study.","authors":"Spencer M Mossack, Antonio Franco, Daniel F Roadman, Morgan R Sturgis, Angelo Orsini, Gabriele Bignante, Francesco Lasorsa, Christopher L Coogan, Edward E Cherullo, Cosimo De Nunzio, Riccardo Autorino","doi":"10.1038/s41391-024-00913-0","DOIUrl":"https://doi.org/10.1038/s41391-024-00913-0","url":null,"abstract":"<p><strong>Background: </strong>Socioeconomic determinants of health (SDOH) are often unvalued during surgery risk stratification; hence, they might be a major source of disparity that can jeopardize outcomes related to urological surgery. The aim of our study is to evaluate the impact of SDOH on postoperative outcomes following minimally invasive radical prostatectomy (MIRP).</p><p><strong>Methods: </strong>Patients who underwent MIRP between 2011 and 2021 were retrospectively analyzed by using PearlDiver-Mariner, an all-payer insurance claims database. International Classification of Diseases diagnosis and procedure codes were used to identify patient's characteristics, postoperative complications and SDOH. Outcomes were compared using multivariable regression models.</p><p><strong>Results: </strong>Overall, 100,035 patients (mean age = 63.24 ± 7.07) underwent MIRP. The 60-day postoperative complication rate was 18%. Approximately 6% of patients reported at least one SDOH at baseline. SDOH were associated with higher odds of 60-day postoperative complications (OR:1.24, 95% CI:1.15-1.34), including urinary tract infection (OR:1.32, 95% CI:1.20-1.45) and acute kidney injury (OR:1.31, 95% CI:1.00-1.39). Postoperative urethral stricture (OR:1.37, 95% CI:0.92-1.98) did not reach statistical significance at multivariable analysis.</p><p><strong>Conclusions: </strong>Patients with SDOH have a significantly higher risk of postoperative complications following MIRP, especially urinary infection and acute kidney injury. These findings are multifactorial and should prompt identifying measures that might help prevent this large-scale phenomenon.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信